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The release of ATP from the urothelium in response to stretch during filling demonstrates the importance of the purinergic system
for the physiological functioning of the bladder. This study examined the effect of P2 receptor agonists on ATP release from two
urothelial cell lines (RT4 and UROtsa cells). Hypotonic Krebs was used as a stretch stimulus. Incubation of urothelial cells with
high concentrations of the P2Y agonist ADP induced ATP release to a level that was 40-fold greater than hypotonic-stimulated ATP
release (P < 0.0011, ADP EC50 1.8𝜇M). Similarly, an increase in ATP release was also observed with the P2Y agonist, UTP, up to a
maximum of 70% of the hypotonic response (EC50 0.62 𝜇M). Selective P2 receptor agonists, 𝛼𝛽-methylene-ATP, ATP-𝛾-S, and 2-
methylthio-ADP hadminimal effects on ATP release. ADP-stimulated ATP release was significantly inhibited by suramin (100𝜇M,
P = 0.002). RT4 urothelial cells break down nucleotides (100 𝜇M) including ATP, ADP, and UTP to liberate phosphate. Phosphate
liberation was also demonstrated from endogenous nucleotides with approximately 10% of the released ATP broken down during
the incubation. These studies demonstrate a role for P2Y receptor activation in stimulation of ATP release and emphasize the
complexity of urothelial P2 receptor signalling.
1. Introduction
The first evidence for P2 receptor signalling from the urothe-
lium was provided in 1997 with the work of Ferguson et al.,
who demonstrated in tissue strips that ATP is released
from the urothelium in response to stretch [1]. Our under-
standing of the sensory role of the urothelium has since
greatly increased, with stretch-induced ATP release from the
urothelium also identified in cultured cells [2] and in vivo
preparations [3].
ATP binds to two families of P2 receptors, P2X ligand-
gated ion channels and G protein-coupled P2Y receptors. To




receptors [5] expressed on the urotheliumandP2X
3
expressed on the urothelium [5, 6] as well as on suburothelial
afferent nerves and myofibroblasts [7]. It is hypothesised
that ATP released from the urothelium interacts with P2
receptors located on both afferent nerves (P2X
3
) [8] and
myofibroblasts to signal bladder fullness. A role for ATP in
bladder dysfunction has been postulated with increased ATP
release associated with sensory disorders such as interstitial
cystitis [9] and painful bladder syndrome [10]. Furthermore,
ATP has been shown to play a role in bladder sensation, with
ATP concentration in the intravesical fluid correlating with
the first desire to void in patients with both overactive bladder
[3] and painful bladder [11] but not in control patients.
P2X receptors are activated preferentially by ATP; thus
urothelial derived ATP may have an autocrine action on
urothelial P2X receptors. However the urothelium also
expresses ectoATPase enzymes [12] and so is able to hydrolyse
ATP (and other nucleotides) to breakdown products such
as ADP, AMP, and adenosine. The perceived function of
these enzymes is to limit the availability of ATP. Recently,
the urothelium has been shown to release nucleotides other
than ATP with twelve nucleotides quantified by HPLC in
patient urine specimens [13]. The levels of ADP, UTP, UDP,
andGTPwere found to bemore than 10 times higher than the
level of ATP [13]. Other epithelial cells have also been shown
to release nucleotides such as ATP, ADP, AMP, adenosine,
UTP, and UDP, in response to hypotonic stimulus [14]. The
role of these nucleotides in P2 receptor signalling in the
bladder is yet to be determined. It is known that in addition
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to ATP, other nucleotides, in particular ADP and UTP, can
also be substrates for P2Y receptors; however, their effects
on urothelial P2Y receptors have not been explored. Eight





[5, 16, 17], P2Y
4





receptors are expressed on suburothelial
myofibroblasts [18] but their expression on urothelial cells
remains controversial [5, 19]. The function of these receptors
on the urothelium is currently undetermined. In addition,
adenosine formed from the breakdown of ATP binds to P1
receptors which are also expressed on the urothelium [20].
It is very clear that the complexity of urothelial P2
receptor signalling and the feedback of ATP breakdown and
release have not been adequately explored to date. Therefore
the aims of this study were to examine the effect of purine
and pyrimidine nucleotides on urothelial cell ATP release.We
hypothesise that purines and pyrimidines selective for P2Y
receptors will modulate ATP release from the urothelium.
2. Materials and Methods
2.1. Cell Culture. Human urothelial RT4 cells were obtained
from the ECACC. Cells were grown at 37∘C with 5% CO
2
in McCoy’s 5A culture medium supplemented with 10%
foetal bovine serum, 100 units/mL of penicillin, 100 𝜇g/mL of
streptomycin, and 0.25 𝜇g/mL of fungizone.When confluent,
RT4 cells were passaged with 0.05% Trypsin-EDTA for 5
minutes and then plated onto T75 flasks for continuous
passage or onto 24 well plates for use in experiments when
confluent (approximately 3 to 5 days after passage).
Human urothelial UTOtsa cells were a gift from Dr.
Scott Garrett from the University of North Dakota. Cells
were grown at 37∘C with 5% CO
2
in Dulbecco’s modi-
fied eagle’s medium supplemented with 5% foetal bovine
serum, 100 units/mL of penicillin, 100 𝜇g/mL of strepto-
mycin, 0.25 𝜇g/mL of fungizone, and 1% glucose. UROtsa
cells were passaged in the manner described above for RT4
cells.
2.2. ATP Release Studies. ATP release was determined as we
have described previously [2]. Urothelial cells were washed
(three times) with carbogenated Krebs-Henseleit solution











2.5, and D-glucose 11.7). The basal level of
ATP release was then determined by a 10-minute incubation
in 500𝜇L Krebs-Henseleit solution. These media were col-
lected and followed with the experimental treatments. Cells
were exposed to normal Krebs-Henseleit (control) or the
indicated concentration of nucleotide. Cells were exposed to
hypotonic Krebs-Henseleit (1 : 2 dilution of Krebs-Henseleit
in distilled water), a stimulus commonly used to mimic
stretch in cultured cells [2]. Cells were treated for 10min
before the supernatant (200𝜇L) was collected and used for
ATP determinations.
ATP concentration in the supernatant was measured
using the bioluminescence assay according to the manufac-
turer instructions. Equal volumes of the cellular supernatant
or ATP standard solutions (10−6 to 10−10M) were mixed
with the bioluminescence assay mix and the luminescence
generated was measured immediately using a plate reader
(BMG labtech Polarstar). The standard concentrations fell
within the upper and lower limits of sensitivity of the ATP
bioluminescence assay. The ATP concentration in the cell
supernatant was calculated relative to the standard curve.
Luminescence was also measured for all concentrations of
the nucleotides used. The luminescence determined for each
concentration of nucleotide was used as a blank for that treat-
ment and was subtracted from the corresponding cellular
luminescence before the ATP concentration was calculated.
Treatments were carried out in triplicate and the mean ATP
concentration (in nM) per treatment determined.
2.3. EctoATPase Studies. Confluent urothelial cells in 24 well
plates were washed (three times) in phosphate free media
(containing mM: NaCl 120, KCl 5, CaCl
2
2, HEPES 20, and
D-glucose 10) [12]. After washing cells were incubated with
100 𝜇M nucleotide. After 30 minutes the supernatant was
collected and the phosphate concentration determined. In
additional experiments confluent cells in 12 well plates were
incubated in control or hypotonic (50% dilution in water)
phosphate free media for 10 or 30 minutes and both ATP
concentration and phosphate concentration determined.
Phosphate liberated from nucleotides was determined as
previously described [21]. Equal volumes of cell supernatant







) were mixed. After 15 minutes
absorbance at 750 nm was measured in a plate reader (BMG
labtech Polarstar). Phosphate concentration in the cell super-





10 to 150 nM). Treatments were carried out in triplicate and
the mean phosphate concentration (in nM) per treatment
determined.
2.4. Statistics. Results are nonnormally distributed and as
such are expressed as median with interquartile range (IQR).
Two different treatments were compared using a Mann-
Whitney 𝑡-test. Concentration response relationships were
examined using a sigmoidal concentration response curve.
All statistics were performed using Graphpad Prims (version
6) (San Diego, CA).
2.5. Materials. All cell culture reagents were purchased from
Invitrogen (Mount Waverley, Australia). Bioluminescence
ATP Assay kit and nucleotides were from Sigma-Aldrich
(Sydney, Australia). All other reagents were of high analytical
grade.
3. Results
3.1. Effect of Nucleotides on Urothelial Cell ATP Release.
Hypotonic Krebs was used as a stretch stimulus and was seen
to induce an approximate threefold increase in ATP release
(𝑃 = 0.0006). Incubation of RT4 cells with ADP (100 𝜇M
for 10 minutes) induced ATP release to a level that was 40-
fold higher compared to the hypotonic stimulus (Table 1, 𝑃 <
0.0011). In the presence of AMP and adenosine, the level of
BioMed Research International 3
Table 1: ATP release in RT4 urothelial cells stimulated by 10-minute
incubation with nucleotides (100𝜇M).
ATP release in RT4 cells
Control 20.28 (13.24–40.22) nM (𝑛 = 33)
Hypotonic 64.63 (43.75–92.95) nM (𝑛 = 33)
ADP 2641 (2006–3598) nM (𝑛 = 13)
AMP 8.56 (4.74–189.2) nM (𝑛 = 17)
Adenosine 5.58 (4.52–65.85) nM (𝑛 = 4)
CTP 51.12 (37.4–99.96) nM (𝑛 = 11)
GTP 55.33 (34.42–173.4) nM (𝑛 = 15)
UTP 60.57 (36.51–126.1) nM (𝑛 = 11)
𝛼,𝛽-Methylene-ATP 26.6 (22.5–77.5) nM (𝑛 = 9)
ATP-𝛾-S 2294 (429–2538) nM (𝑛 = 16)
Table 2: ATP release in UROtsa urothelial cells stimulated by 10-
minute incubation with nucleotides (100 𝜇M).
ATP release in UROtsa cells
Control 11.08 (4.3–30.2) nM (𝑛 = 6)
Hypotonic 68.3 (35.6–133.4) nM (𝑛 = 6)
ADP 3377 (752–6361) nM (𝑛 = 6)
UTP 61.2 (26.6–115.7) nM (𝑛 = 6)
2-Methylthio-ADP 17.7 (13.9–26.9) nM (𝑛 = 6)
ATP release was not significantly different to the control level
(Table 1).The response to CTP and GTP was not significantly
different to the ATP release induced by hypotonic media
(Table 1).
When the concentration response effect of ADP induced
ATP release was determined it was seen to only occur at high
concentrations of ADP (Figure 1(a)) with an EC50 of 1.8 𝜇M
determined (𝑛 = 5). A concentration dependent inhibition of
ATP release was seen with AMP (Figure 1(b)) with an EC50
of 0.33 𝜇M (𝑛 = 7). A concentration dependent increase in
ATP release was observed with UTP, up to a maximum of
approximately 70% of the hypotonic response (Figure 1(c)).
An EC50 of 0.62 𝜇Mwas determined (𝑛 = 7).
In RT4 cells, concentration response relationships were
also determined for P2 receptor agonists and antagonists.The
P2X agonist, 𝛼𝛽-methylene-ATP, and P2Y agonist, ATP-𝛾-S,
had no effect on ATP release (Figures 2(a) and 2(b), 𝑛 = 9
and 15, resp.).Themore selective P2Y
1
agonist, 2-methylthio-
ADP, inhibited ATP release in a concentration dependent
manner (Figure 2(c), EC50 0.16 𝜇M, 𝑛 = 8).
P2 receptor antagonists were investigated for their ability
to inhibit ADP-stimulated ATP release. PPADS (100 𝜇M) had
no effect on ADP-stimulated ATP release (88.4 (65.2–113.4)%
of ADP-stimulated release, 𝑛 = 8, 𝑃 = 0.4) while suramin
(100 𝜇M) significantly inhibited ADP-stimulated ATP release
(43.3 (27.6–41.7)%ofADP-stimulatedATP release,𝑃 = 0.002,
𝑛 = 4; IC50 8.3 𝜇M, 𝑛 = 8).
The results observed in RT4 urothelial cells were also
confirmed in UROtsa cells (Table 2). Similar to the results
observed in RT4 urothelial cells, treatment of UROtsa cells
with hypotonic Krebs induced an increase in ATP release
(𝑃 = 0.0087). Incubation of UROtsa cells with ADP (100 𝜇M
Table 3: Phosphate liberation from 30-minute incubation of RT4








for 10 minutes) induced an almost 50-fold increase in ATP
release compared to that seen with the hypotonic stimulus
(𝑃 < 0.0022). UTP (100 𝜇M) initiated ATP release similar
to that seen with hypotonic stimulus while 2-methylthio-
ADP (100 𝜇M) elicited an ATP release response similar to the
control level.
3.2. EctoATPase Activity of Urothelial Cells. RT4 urothelial
cells were shown to have the capacity to liberate phos-
phate from nucleotides (100 𝜇M), with the greatest amount
of phosphate liberated from ADP and UTP (Table 3). In
addition, a small amount of phosphate liberation was able
to be demonstrated from endogenous nucleotides released
during the experiment (Figure 3). When RT4 cells were
incubated in either control or hypotonic phosphate free buffer
for 10 or 30 minutes, significant ATP release was induced
(Figure 3(a), 𝑛 = 8). After a 10-minute incubation the level
of release in the control was approximately 40 nM and in
hypotonic phosphate free media was approximately 80 nM
which was comparable to that seen using Krebs-Henseleit
solution (Table 1). Over the 10- or 30-minute incubation some
of this endogenous ATP was broken down by RT4 cells
to liberate phosphate that could be detected (Figure 3(b),
𝑛 = 8). Significantly more phosphate was detected in cells
treated with hypotonic media for 10 and 30 minutes (𝑃 =
0.0002 and 0.0019, resp.). After a 10-minute incubation the
level of phosphate liberated indicated that approximately 10%
(7 to 15%) of the endogenously released ATP was broken
downduring the incubations in control and hypotonicmedia,
respectively. In the presence of the ectoATPase inhibitor
ARL67156 (100 𝜇M) the amount of ATP detected in cells
treated with hypotonic phosphate free buffer increased 5-fold
after both 10- and 30-minute incubations (Figure 3(c), 𝑛 = 4).
4. Discussion
The demonstration of ATP release from the rabbit bladder
urothelium in response to stretch by Ferguson and colleagues
in 1997 [1] has been pivotal to our understanding of signalling
within the bladder.However, our understanding of the factors
that modulate ATP release and the autocrine signalling that
occurs at the urothelial cell layer is limited. The current
study has demonstrated that P2 receptor agonists are able
to stimulate ATP release from urothelial cells. In fact the
P2Y agonist ADP was shown in two urothelial cell lines,
to stimulate a level of ATP release that is far in excess of
4 BioMed Research International
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Figure 1: Concentration response relationships for nucleotides ADP (a), AMP (b), and UTP (c) on RT4 urothelial cell ATP release.
that stimulated by hypotonic media. Similarly, UTP, another
P2Y agonist [22], was also shown to stimulate ATP release,
although to a lesser extent. In contrast, P2X agonists such as
𝛼,𝛽-methylene-ATP were not seen to stimulate ATP release
from cultured urothelial cells. These results are similar to
the recently published findings by Sui and colleagues who
reported that the P2Y agonist UTP stimulated ATP release
in guinea pig and human bladder mucosal strips, while the
P2X agonist 𝛼,𝛽-methylene-ATP had no effect [22]. UTP
stimulated ATP release has also been reported from primary
cultures of rat bladder urothelial cells [17].







[16, 17], and P2Y
11
[5] receptor subtypes are present
in bladder urothelial cells (see introduction). While P2X
receptors respond preferentially to ATP, P2Y receptors are


















) [23]. Of the P2Y receptors that






respond to ADP while P2Y
11
receptors respond to ATP [23].
In the current study, ATP release was stimulated by both
ADP and UTP, although the release elicited by ADP was far
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Figure 2: P2 receptor agonist stimulated ATP release. Incubation of RT4 urothelial cells with increasing concentration of 𝛼,𝛽-methylene-ATP
(a), ATP-𝛾-S (b), and 2-methylthio-ADP (c).
greater than that elicited by UTP, suggesting the involvement
of more than one P2Y receptor subtype. The EC50 value




receptors. This is in agreement with previously
reported EC50s at P2Y
1
of 0.9–8 𝜇M [24–26]. The effects




receptors, agreeing with previously reported EC50s
(0.14–0.8 𝜇M) at the P2Y
2
receptor [24, 25] and P2Y
4
receptor
(2.5 𝜇M) [24, 25]. In contrast, the selective P2Y
1
agonist, 2-
methylthio-ADP [26], did not stimulate ATP release. The
current study therefore suggests that more than one P2Y
receptor subtype is likely to be involved in nucleotide stimu-
lated ATP release. Unfortunately, the lack of subtype selective
agonists for individual P2Y receptors makes it difficult to
definitively identify the receptor subtypes involved in the
observed responses.
It is possible that the apparent ATP release stimulated
by high concentrations of ADP was due to the conversion
of ADP to ATP by cell membrane-bound adenylate kinase.
While this enzyme is predominately intracellular [27], it has
been identified on the cell membrane of endothelial cells
[28] and other cell types [27] although there have been no





























































P = 0.029 P = 0.028
(c)
Figure 3: Phosphate liberation from endogenously released ATP. Incubation of RT4 urothelial cells in control or hypotonic phosphate free
buffer for 10 or 30 minutes induced ATP release (a). Over the 10- or 30-minute incubation a small amount (approximately 10%) of this ATP
was broken down by urothelial cells to liberate phosphate that could be detected (b). The presence of the ectoATPase inhibitor ARL67156
(100𝜇M) was seen to increase the amount of ATP detected after both 10 and 30 minutes (c).
reports of cell membrane-bound adenylate cyclase in the
urothelium. However, coincubation of ADP with the P2
receptor antagonist suramin inhibited ADP-stimulated ATP
release, suggesting that it is indeed P2Y receptors that are
involved in this response (reported IC50s 3–50 𝜇M) [15].
The source of ADP in vivo is unknown; however, nucle-
otides have recently been isolated from human urine samples
[13]. In addition, urothelial cells express ectonucleotidase
enzymes capable of degrading ATP and UTP to their respec-
tive nucleotides [29]. The basal and intermediate cells of
the mouse bladder urothelium express NTPDase 3 [29].
Similarly, the human urothelial cell line RT4 used in the
current study expresses NTPDase 3 and 5 [12] but not
NTPDase 1 [12, 30]. NTPDase 1, 2, and 3 are known to face
the extracellular environment and catalyse the breakdown of
extracellular ATP [29]. It is thought that ectoATPase enzymes
function to limit the exposure of P2 receptors to their ligands
and tomodulate the autocrine response to released ATP [29].
In the current study the activity of ectoATPase in
urothelial RT4 cells was examined in three ways. Firstly,
ectoATPase enzymes present on the RT4 urothelial cells
were able to liberate phosphate from stretch-induced ATP
release, indicating a capacity to generate mediators such as
ADP from stretch-induced ATP release. Secondly, incuba-
tion of the ectoATPase inhibitor ARL67156 (100 𝜇M) [31]
resulted in a higher level of stretch-induced ATP release
being detected. At this concentration, ARL67156 has been
shown to inhibit the activity of NTPDase3 (Ki 18 𝜇M) [32].
Finally, we demonstrated the capacity of ectoATPase enzymes
associated with RT4 urothelial cells to liberate phosphate

















Figure 4: Hypothetical schematic representation of the complexity
of the effect of nucleotides and stretch on urothelial cell ATP release.
from exogenous nucleotides including ATP, ADP, AMP, CTP,
GTP, and UTP. Similarly, Stella and associates showed that
RT4 urothelial cells were able to liberate phosphate from
exogenous nucleotides [12].
The results obtained in the current study demonstrate
that P2 receptor signalling in the urothelium is a complex
interaction between ATP release and breakdown. To add to
the complexity, it now seems likely that products formed from
breakdown of nucleotides such as ATP also have affects at
P2 receptors located on the urothelium. Our understand-
ing of this complex interaction between ATP release and
breakdown has been shown schematically in Figure 4. ADP
has been previously postulated to stimulate urothelial ATP
release [9] and to activate intracellular calcium transients
[5, 33] that were greater than those activated by hypotonic
solutions [33], a commonly used stimulus for ATP release.
It was proposed that the ATP-dependent calcium transients
were mediated by urothelial P2Y (rather than P2X) receptors
[5, 33]; however, it is known that ATP has a low affinity at
P2Y receptors [23, 25]. It is therefore possible that the calcium
transients induced by endogenous ATP were in fact due to
the generation of ADP by membrane-bound ectoATPases.
This is supported by the findings of the current study which
demonstrate that ADP is capable of stimulating ATP release.
Adding to the complexity of P2 receptor signalling, further
breakdownofADP toAMPand adenosinewas seen to inhibit
ATP release. Inhibition of ATP release by adenosine has been
previously reported in rabbit bladder mucosal strips [20].
These findings indicate that while the initial breakdown of
ATP to ADP may exert positive feedback for ATP release
which is short lived, further breakdown of ATP to AMP and
adenosine may provide negative feedback for ATP release.
Activation of urothelial P2Y receptors has been proposed
to be responsible for a number of physiological functions
of the urothelium. Exogenous application of P2Y receptor
agonists, includingADPandUTP, has been shown to increase
spontaneous activity in rat bladder sheets [34]. Similar to the
results seen in this study, it was unlikely that a single P2Y
receptor subtype was responsible for the reported increase









being hypothesised. In addition,
activation of P2Y
2
receptors leads to release of the inflam-
matory mediators interleukins 8 and 6 from uroepithelial
cells [35], indicating a role for activation of P2Y receptors
in inflammatory responses in the bladder. Interestingly,
expression of the P2Y
2
receptor decreased in a feline model
of interstitial cystitis [16]. Intravesical instillation of a P2Y
6
selective agonist induced bladder overactivity characterised
by increased voiding frequency in a rat cystometry model in
addition to increased ATP release into the voided fluid [19].
Alterations in urothelial ATP release have been identified
in bladder dysfunction including interstitial cystitis [9],
painful bladder syndrome [10, 11], and overactive bladder [3].
The results of this study demonstrate the complexity of P2
receptor signalling in the urothelium by elucidating a role
for a number of P2Y receptor subtypes in initiating ATP
release. Recent literature has shown the important role of
these receptors in normal bladder physiology, indicating that
these receptors may represent a potential future target for the
treatments of bladder dysfunction.
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